Ampio appoints Dr David Stevens to board
This article was originally published in Scrip
Ampio Pharmaceuticals, a drugs development company, has appointed Dr David Stevens to its board as an independent director. Dr Stevens is currently executive chairman of Cedus and serves on the board of Poniard Pharmaceuticals, Micro-Imaging Solutions, and Aqua Bounty Technologies. He will replace Michael Macaluso, though Mr Macaluso will retain his position as chairman of the board.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.